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Membrane and membrane-associated proteins
involved in the aggressive phenotype displayed by
highly invasive cancer cells
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Invasion, the penetration of tumour cells into adjacent tissues, is a fundamental characteristic of
malignant carcinomas and a first step in the metastatic process. The molecular mechanisms
involved in tumour cell invasion are complex, but over the last couple of decades the knowledge
base has grown quite considerably and many proteins with important roles in invasion have been
identified and characterised. Benign tumours typically are encapsulated, which inhibits their
ability to behave in a malignant manner, meaning these tumours do not grow in a location-lim-
ited less aggressive manner, do not invade surrounding tissues and do not metastasise. The
ability of malignant tumours to invade and metastasise is the major cause of death for cancer
patients. A greater insight into the molecular basis of cancer invasion and metastasis will lead to
the development of novel therapies and specific panels of biomarkers for use in the treatment
and diagnosis/monitoring in many types of metastatic cancer.
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1 Introduction
The abilities of cells to invade and metastasise are critical
features of cancer. Metastasis is defined by the ability of
tumour cells at the primary site to invade local tissue, cross
basement membranes/tissue barriers and to re-establish at
distant secondary locations. To initiate separation of a
malignant cell from the tumour mass, cancer cells must first
break signalling contact with neighbouring cells, degrade
and penetrate the basement membrane and then invade the
interstitial stroma in order to reach blood/lymph vessels [1].
Intravasation requires penetration of the blood/lymph sys-
tems. The tumour cells must then exit the lymph system or
blood stream at a new site (extravasation) and proliferate in
the secondary organ [2].
The three step model for tumour invasion (degradation,
adhesion and migration of cancer cells) has proved to be the
basis for much research in the field of tumour invasion and
metastasis [3]. Degradation of the basement membrane and
interstitial connective tissue requires the production of
extracellular proteases that are secreted in high concentra-
tions from the invading tumour front.
During the metastatic cascade adhesion molecules seem
to be missing or are compromised. For example, epithelial
(E)-cadherin is frequently partly or entirely downregulated in
cancer cells, facilitating detachment from each other and
from the extracellular matrix (ECM). To migrate, the cell
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body must modify its shape and elasticity to interact with the
surrounding tissue structures. Cell migration through tis-
sues results from a continuous cycle of steps, including the
formation of lamellipodia, filopodia, pseudopodia or invado-
podia at certain distinct time points during the migration
process.
This review will focus on membrane and membrane-
associated protein involvement in many of the inter-
dependent steps in tumour cell invasion, how this leads to
metastatic growth in distant organs and the impact of partic-
ular protein as drug targets and as markers of disease state.
2 In vitro model of invasion
2.1 General
Typically, during tumour progression and malignant trans-
formation, epithelial cells acquire mesenchymal properties
because of the epithelial to mesenchymal transition (EMT).
EMT is a typical feature of aggressive, invasive and meta-
static cancer cells. In vitro, the morphology of highly invasive
cancer cells can reflect the characteristics of EMT, such as
loss of cell adhesion (E-cadherin) and increased cell motility.
Cells undergoing EMT display a scattered spindle shaped
morphology, whereas noninvasive cells remain in tight com-
pact epithelial colonies (Figs. 1A and B).
Various in vitro models have been developed to investi-
gate the molecular mechanisms associated with invasion and
to explore the effects of certain pharmacological agents on
this process. As with most cell culture models, the in vitro
invasion assay may not be a perfect representation of the in
vivo phenotype, but over the last number of decades it has
proved to be a valuable source of information and has
undoubtedly increased our overall understanding of the
complex interdependent processes involved in cancer cell
invasion. Two main areas in proteomics, namely expression
and function-based platforms, have been extensively exam-
Figure 1. (A) Morphology of a
highly invasive breast cancer
cell line, MDA-MB-231 with
elongated and spindle-like phe-
notype. (B) Noninvasive breast
cancer cell line, MCF-7 with epi-
thelial tight colonies. (C) and (D)
Highly invasive and non/low
invasive clonal populations of
the pancreatic cancer cell line,
MiaPaCa-2 displaying character-
istic morphology. Magnifica-
tion, 4006. Scale bar 100 mm. (E)
Cell invasion assay representing
the highly invasive pancreatic
clonal cell line invading through
ECM coated Boyden chamber,
stained with crystal violet. (F)
Cell invasion assay representing
the low/noninvasive pancreatic
clonal cell line invading through
ECM coated Boyden chamber.
Magnification, 2006. Scale bar
200 mm.
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ined using cell culture models of invasion. Expression pro-
teomics has allowed for the identification of proteins found
to have changed abundance levels in invasive compared to
noninvasive phenotypes. Functional proteomics approaches
have facilitated researchers gaining more concentrated
information on specific proteins through the use of siRNA
knockdown and cDNA overexpression systems, modern im-
aging analysis and protein–protein interaction studies.
2.2 Invasion assay
The Boyden chamber chemoinvasion assay, developed first
by Albini et al. [4] is still widely used to study the invasive
potential of cell culture models in vitro. In general, cells are
placed in the upper compartment and are allowed to migrate
through the pores of the membrane into the lower compart-
ment, in which chemotactic agents are present. Using dif-
ferent matrices to mimic the basement membrane, the
invasion chamber serves as a model to investigate the
tumour cells ability to penetrate into and through the ECM
and towards a chemoattractant. Pro- or anti-invasion factors
can be added to the upper chamber containing the tumour
cells to investigate their specific effects. Cells are given a
fixed period of time to adhere to and penetrate the ECM with
noninvading cells located on the upper surface of the filter
and invading cells on the lower chamber. Invading tumour
cells are generally fixed, stained and counted thereafter or
used to establish an invasive subpopulation of tumour cells
(Figs. 1C and D). Many different aspects of the assay can be
altered including the size of the pores in the membrane, the
coating of the lower chamber including the use of collagen I,
fibronectin or gelatin which serve as chemoattractants and
also the cell density used initially.
The selection of cancer cell lines with chemotherapeutic
agents can alter the invasive potential of cells, resulting in a
superinvasive phenotype, where cells not only invade
through Matrigel and migrate through membrane pores, but
also subsequently survive in suspension and ultimately
attach to and grow on the bottom of the well beneath the
insert. In our laboratories, Glynn et al. [5] demonstrated that
selection of the human cell line MDA-MB-435S-F with doxo-
rubicin and paclitaxel resulted in a more aggressively inva-
sive phenotype, termed superinvasion.
3 Extracellular matrix (ECM) degradation
Degradation of the ECM is an essential step in tumour cell
invasion and metastasis. The ECM contains many compo-
nents including proteoglycans, collagens, fibronectins, elas-
tins and laminins. Integrins are cell surface proteins that
bind cells to ECM structures, such as fibronectin and lami-
nin, activating pathways that lead to the degradation of the
ECM by specific enzymes such as the matrix metalloprotei-
nases (MMPs) and the urokinase-type plasminogen activator
(uPA) system in invasive tumour cells.
3.1 Integrins
As the main link between a cell and the ECM, integrins have
an essential role in the invasion process. Integrins are a large
family of heterodimeric proteins which transduce a variety of
signals from fibronectin and other ECM molecules. They are
composed of a larger alpha (a) and smaller beta (b) subunits.
Both contain a large extracellular domain, a membrane-
spanning region, and a relatively small cytoplasmic domain.
The extracellular parts of the two subunits associate non-
covalently to form a functional receptor. Integrins are formed
from 18 a and 8 b subunits, which dimerise to yield at least
24 different integrin heterodimers, each with distinct ligand
binding and signalling properties. Ligand occupancy is criti-
cal for activation of integrin signalling involving many dif-
ferent pathways and the fibronectin–integrin interactions are
important in tumour cell migration, invasion and metas-
tasis.
The role for specific integrins and their associated
ligands in intracellular signalling pathways has been de-
scribed in a number of tumour types, and often multiple
integrins are involved within a single tumour type. For exam-
ple, during attachment to lymph nodes, melanoma cells uti-
lise avb3-vitronectin binding interactions, whereas breast can-
cer cells utilise integrin a3b1-fibronectin binding [6]. Integrin
a2b1 was originally characterised as a melanoma progression
antigen and measurement of this receptor might be used as
predictive markers when assessing disease progression [7].
Modern proteomics labelling technologies have been
employed by several groups to identify integrins and other
proteins involved in specific invasive phenotypes being
investigated. Chen et al. [8] used ICAT (isotope-coded affinity
tag) and MS/MS to perform quantitative proteomic profiling
of pancreatic cancer tissues and normal pancreas to identify
proteins associated with invasion and metastasis. Their
results indicated many proteins with elevated abundance
levels in the pancreatic cancer proteome compared to the
control, including integrin b1, a result that was confirmed by
Western blotting and immuno-histochemistry (IHC). Using
iTRAQ reagents, followed by 2-D LC-MS/MS, Keshamouni et
al. [9] identified a total of 51 differentially expressed proteins
during TGF-beta induced-EMT in the human lung cancer
cell line A549. Proteins found upregulated included integrin
b1 and cofilin, suggesting the acquisition of an invasive
phenotype.
Integrin-mediated degradation of the ECM and asso-
ciated tissue is an important first step of invasion. The role of
the integrins is not limited to their function as a mechanical
bond in cell–matrix contact sites, but, after binding extra-
cellular ligands, integrins are also capable of sending signals
into the cell. The basement membrane is a thin sheet com-
posed of a mixture of ECM proteins, including laminins,
collagens and proteoglycans produced in part by the epithe-
lial cells themselves and in part by underlying connective
tissue cells (specifically, fibroblasts). Interference in the reg-
ular functioning of the basement membrane is a key histo-
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logical marker of a tumour’s transition to an invasive carci-
noma. Degradation of the basement membrane requires the
expression of specific proteases that target unique members
of the ECM. This targeting by certain proteases in tightly
regulated, with a continually changing balance existing be-
tween active proteases and their inhibitors, preventing excess
matrix degradation.
Amongst the proteases activated by up-stream stimula-
tion of integrin receptors are a family of proteins named the
MMPs. They are active on a relatively broad range of targets
including collagen, plasminogen, elastin, fibronectin, lami-
nin and the urokinase plasminogen activator receptor
(uPAR). MMPs are secreted as inactive zymogens (pro-
MMPs) that require proteolytic activation, much of which
occurs at the cell surface and involves many membrane or
membrane-associated proteins. For example, cell surface
activation of an MMP can occur when gelatinase A (MMP-2)
is brought into contact with a membrane-associated MMP,
MT-1 MMP [10, 11]. MMP-2 and MMP-9 (gelatinase B) have
their greatest enzymatic activities against type IV collagen,
which is the main constituent of the basement membrane
[12, 13].
Integrins can regulate the expression of the MMPs
genes and they have also been shown to influence the
secretion of the granule-stored MMPs and the activation of
the latent protease at the cell surface. One of the best
characterised of these pathways is the mitogen activated
protein kinase (MAPK) cascade. This serial phosphoryla-
tion of substrate proteins terminates in activation of tran-
scription factors which regulate expression of target genes.
Many of these genes are critical for ECM degradation or
cell migration.
A complex series of interactions, starting with the initial
stimulation of the integrin receptor and subsequent activa-
tion of intracellular pathways are responsible for maintain-
ing the precise degradation on the ECM. In the course of
tumour cell invasion and migration, interactions with inte-
grins and the ECM are constantly been formed and broken
and depending on the type of ligand occupying the receptor
site, a different series on intracellular cascades are set in
motion.
3.2 uPAR and galectins
An important factor implicated in tumour cell predisposi-
tion for invasion is the malignancy-related upregulation of
uPAR. uPAR is a cysteine rich glycoprotein (about 55–
60 kDa) attached to the plasma membrane (PM) via its car-
boxy-terminal to a glycosyl phosphatidyl inositol (GPI)
anchor. uPAR can bind to available pro-uPA and, upon
activation, uPA can bring about degradation of ECM leading
to invasion/metastasis by stimulating tyrosine kinase and
subsequent downstream signalling pathways. Margheri et
al. recently examined the effects of inhibiting uPAR signal-
ling by inhibition of uPAR expression with antisense oligo-
nucleotides (aODNs) in PC3 human prostate cancer cells
and evaluated aODN effect in a mouse model of prostate
cancer bone metastasis. There results demonstrated that
PC3 cells adhesion was unaffected, while proliferation and
invasion of Matrigel were impaired. Mice injected with PC3
cells and treated with aODN to uPAR revealed an 80%
reduction in bone metastasis as compared to the control
groups [14].
Galectins have important functions in cell–cell interac-
tions, cell adhesion to ECM, the organisation of ECM and
tissue remodelling. Although galectins lack a transmem-
brane domain (TMD), these proteins are known to func-
tion at the cell surface. Galectins seem to play a role in the
expression of integrins on the cell surface, promoting
interactions with fibronectin, laminin, vitronectin, collagen
and other cell membrane proteins. Altered expression
levels of galectin-1 and galectin-3 are often associated with
the invasive potential of cancer cells. Tsuboi et al. [15]
recently showed that the reduction of galectin-3 expression
is associated with the invasion and metastasis of colorectal
cancer using immunohistochemical assessment at the
tumour surface and the invasive front. A possible involve-
ment of galectin-3 expression in tumour invasion, metas-
tasis and proliferation in patients with colorectal cancer is
suggested. Employing IHC and reverse transcription-
quantitative PCR assay Chiang et al. [16] suggest that
galectin-1 upregulation at the tumour invasion front might
be a predictor of early metastasis in oral carcinogenesis.
Previous work on galectin-3 in our laboratory showed that
galectin-3 cDNA transfection into the human nonsmall
cell lung carcinoma cell line, DLKP, resulted in enhanced
adhesion to ECM components, cell motility and in vitro
invasiveness [17]. Another study in our laboratory demon-
strated increased levels of galectin-3 in superinvasive cells
(Fig. 2) from isolated membrane fractions using 2-D DIGE
and MS [18]. These superinvasive cells also displayed
reduced attachment to ECM proteins coupled with
increased motility.
4 Adhesion proteins
Interactions either among cells (cell–cell) or between cells
and substratum components (cell–matrix) are mediated by
adhesion molecules. Cancer cells have been shown to
express most of the adhesion receptors found on the surface
of normal cells. Changes in the abundance levels of various
adhesion molecules at specific time points have been pro-
posed to be necessary in order for the complex process of
invasion to progress [19]. More recently, adhesion molecules
have been considered as potential biomarkers in the diag-
nosis, prognosis and treatment in many cases of human
cancer. Cell surface adhesion molecules play vital roles in
numerous cellular processes, including cancer cell invasion.
There are five major families of cell adhesion molecules
(CAMs) including Ig superfamily CAMs, integrins, cadher-
ins, selectins and CD44.
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Figure 2. 2-D DIGE analysis of MDA-MB-435S-F and MDA-MB-
435S-F/Taxol10p4pSI membrane proteins. Shown here is the
abundance levels for Galectin-3, a protein involved in cancer cell
invasion. Galectin-3 was found to be approximately two-fold
increased in the superinvasive cells compared to the parental
cells. Images were generated using the BVA module of DeCyder
software. Galectin-3 was identified using LC-MS yielding four
matched peptides (FNENNR; VIVCNTK; IALDFQR; LDNNWGR)
resulting in a 17.4% sequence coverage.
4.1 Cadherins
Cadherins are cell surface membrane glycoproteins capable
of mediating cell–cell adhesion in a calcium-dependent
fashion. The three most common cadherins are neural (N)-
cadherin, placental (P)-cadherin and E-cadherin. Many in
vitro and in vivo studies primarily focusing on E-cadherin
have demonstrating that loss of expression and function is
closely related to induction of invasiveness and metastatic
potential [20, 21].
E-cadherins mediate homotypic adhesions in epithelial
tissue, bonding epithelial cells together and relaying signals
between the cells. In several epithelial tumours, including
adenocarcinomas of the colon and breast, there is a down-
regulation of E-cadherin expression. The down-regulation
reduces the ability of cells to adhere to each other and facil-
itates their detachment from the primary tumour and their
advance into the surrounding tissues. It has been proposed
that the loss of E-cadherin-mediated cell–cell adhesion is a
prerequisite for tumour cell invasion and metastasis forma-
tion [22].
Jiang et al. combined 2-DE separation and MS identifica-
tion to analyse a pair of highly and poorly metastatic sublines
(termed PLA801D and PLA801C, respectively). Ectopically
expressed interleukin 18 (IL-18) promoted cell motility in
vitro and downregulated E-cadherin expression of PLA801C
transfectants, while IL-18 antisense remarkably decreased
cell invasion potency in vitro and notably increased E-cad-
herin expression of PLA801D transfectants [23].
E-cadherins are linked to the cytoskeleton by the cate-
nins, proteins that lie under the PM. The normal function of
E-cadherin is dependent on its linkage to catenins. In some
tumours, E-cadherin is normal, but its expression is reduced
because of mutations in the gene for a catenin [24].
The loss of E-cadherin function during tumour progres-
sion can be caused by various genetic or epigenetic mechan-
isms. In some cancers, including bladder and gastric, the E-
cadherin gene is mutated, leading to the expression of a
nonfunctional protein [25]. In the majority of cancers, E-
cadherin expression is downregulated at the transcriptional
level, by proteins including Snail and Slug that bind to E2
boxes in the promoter of the E-cadherin gene [26].
In several human cancer types, including melanoma,
prostate and breast cancer, loss of E-cadherin function is
accompanied by de novo expression of mesenchymal cadher-
ins, such as N-cadherin and cadherin-11. The switch from E-
cadherin to N-cadherin expression might provoke the
tumour cell to move into different surroundings and invad-
ing the underlying stroma. E-cadherin is expressed by epi-
thelial cells whereas mesenchymal cadherins are found in
stromal cells such as fibroblasts [27].
4.2 Igs and CD44
The Ig superfamily CAMs are calcium-independent trans-
membrane glycoproteins. Members of the Ig superfamily
include the intercellular adhesion molecules (ICAMs), vas-
cular-CAM (VCAM-1), platelet-endothelial-CAM (PECAM-1)
and neural-CAM (NCAM). Each Ig superfamily CAM has an
extracellular domain, which contains several Ig-like intra-
chain disulphide-bonded loops with conserved cysteine resi-
dues, a TMD and an intracellular domain that interacts with
the cytoskeleton. Typically, they bind integrins or other Ig
superfamily CAMs.
Some CAMs of the Ig superfamily are often found to
have altered levels during the growth and progression of
certain tumours. These alterations in abundance levels of
certain Ig’s on the cell surface may facilitate migration of
tumour cells from the primary lesion through their adhe-
sive activities, resulting in invasion and disseminating
metastasis [28]. Three major isoforms of NCAM are gener-
ated by alternative splicing, which differ in their mem-
brane association and their intracellular portions: NCAM
180 (180 kDa) and NCAM 140 (140 kDa) are transmem-
brane proteins with cytoplasmic tails of different lengths,
whereas the 120 kDa isoform NCAM 120 is anchored to
the membrane by means of glycosylphosphatidyl-inositol
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2008, 8, 4054–4065 Animal Proteomics 4059
(GPI). In various tumour types, N-CAM expression shifts
from the adult 120 kDa isoform to the embryonic 140 and
180 kDa isoforms [29], increasing the invasive potential of
the cancer cells. Perl et al. [30] demonstrated that using the
Rip1Tag2 transgenic mouse model, the abrogation of N-
CAM expression in pancreatic b-cell tumours resulted in a
dramatic increase in the incidence of metastases, pre-
dominantly to local lymph nodes. The precise mechanisms
by which N-CAM impacts on the invasive potential of
many tumour types remains incomplete, but the interac-
tion with the fibroblast growth factor receptor (FGFR) is
crucial leading to the activation of a complex series of
intracellular events [31, 32].
The CD44 protein is a type I transmembrane glycopro-
tein receptor involved in cell–cell interactions, cell adhesion
and migration. The principal ligand of CD44 is hyaluronic
acid, an integral component of the ECM. Other CD44 ligands
include osteopontin, serglycin, collagens, fibronectin and
laminin. Stimulation of CD44 by one of its various ligands
results in intracellular signalling involving Rho/Ras and
activated tyrosine kinase pathways as well as the proteolytic
generation of a fragment of CD44 that seems important as a
signalling molecule. Lopez et al. reported that invasion of
CD44-positive tumour cells was inhibited in hyaluronan-
containing matrices, whereas blocking CD44-hyaluronan
association increased invasion. Collectively, this data shows
that during breast cancer progression, hyaluronan-CD44
dynamics occurring through epithelial–stromal interactions
are protective against metastasis [33].
5 Membrane and membrane-associated
proteins involved in cell migration
Cell migration is a critical step in tumour invasion and
metastasis. Cell migration involves multiple processes that
are regulated by various molecules including many mem-
brane and membrane-associated proteins. The actin cyto-
skeleton and its regulatory proteins are crucial for cell
migration in invasive tumour cells. Actin cytoskeletal reor-
ganisation is essential for tumour cell migration, adhesion
and invasion.
5.1 Actin remodelling
Cells use two kinds of protrusions, filopodia and lamellipo-
dia, to migrate forward propelled by actin polymerisation at
the leading edge. Filopodia and lamellipodia differ in respect
to their actin organisation and the signalling pathways that
are activated.
Degradation of the ECM by cancer or stromal cells
involves specialised actin-rich adhesions, called podosomes
and invadopodia. Both structures are dependent on actin
organisation and dynamics, similar to lamellipodia and filo-
podia. Podosomes and invadopodia contain a variety of pro-
teins involved with actin filaments, actin binding proteins,
adhesion proteins, matrix proteinases and signalling pro-
teins that regulate the actin cytoskeleton and membrane
remodelling.
Extensive actin polymerisation at the leading edge
requires the activity of cofilin, a member of the ADF/cofilin
family that associates with cytoskeletal proteins when acti-
vated. Cofilin is essential for the regulation of actin poly-
merisation and depolymerisation during tumour cell moti-
lity and invasion. Upon receptor stimulation, cofilin nucle-
ates actin polymerisation by severing actin filaments to
generate free barbed ends and also increases the rate of actin
depolymerisation. Yamaguchi et al. proposed a model for
invadopodium formation where cofilin may be required for
optimising Arp2/3 complex-mediated dendritic nucleation to
cause elongation of the invadopodia and its stabilisation.
From data collected in our research laboratories, a significant
increase in the abundance of cofilin and several cytoskeletal
structural/regulatory proteins was found to have an impor-
tant role in mechanisms associated with superinvasion and
other invasive model systems [18, 34–37].
Beckner et al. described a novel two-step method for har-
vesting pseudopodia (invadopodia) to provide material for
proteomic analysis. Differences in the protein profiles of
pseudopodia and whole cells were found using DIGE and
immunoblotting. Met and actin along with other proteins
associated with invasion and metastasis were increased in
pseudopodial lysates on immunoblots when compared to
whole cells and according to the author, represent ther-
apeutic targets to consider for suppression of tumour inva-
sion [38].
5.2 Receptors stimulation and cytoskeletal
reorganisation
Cell migration and invasion are triggered by a number of
chemoattractants. Upon binding to cell surface receptors,
these chemoattractants stimulate intracellular signalling
pathways that regulate reorganisation of the actin cytoskele-
ton. In many different cancer cell types the prognosis of a
patient is inversely correlated with the overexpression and/or
amplification of the epidermal growth factor receptor
(EGFR) family [39]. Accumulating evidence suggests that
EGFR ligands and the EGFR signalling pathway are critical
for the invasiveness and metastasis of cancer cells (Fig. 3).
The EGFR (EGFR; ErbB-1; HER1 in humans) is the cell-sur-
face receptor for members of the epidermal growth factor
(EGF)-family of extracellular protein ligands. The EGFR is a
member of the ErbB family of receptors, a subfamily of four
closely related receptor tyrosine kinases: EGFR (ErbB-1),
HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4).
Yamaguchi et al. [40] demonstrated that EGFR signalling
is necessary for invadopodium formation and may be an
initial key step of cancer cell invasion and metastasis induced
by activation of EGFR signalling. Stimulation of the EGFR,
recruitment and activation of Nck1 and Cdc42 leading to
the activated Neural Wiskott-Aldrich Syndrome Protein
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Figure 3. Invasive tumour cell.
This diagram represents some
of the membrane and mem-
brane-associated proteins
involved in the invasive pheno-
type of many tumour cells. The
activation of many membrane
proteins including CD44 and the
integrin receptors co-activates
the expression of many other
membrane proteins leading to
an increase in the invasive
potential of tumour cells. Also
shown here is a selection of
intracellular and extracellular
events involved in invasion.
(N-WASP) induces actin polymerisation through Arp2/3
complex that drives invadopodium initiation [41]. In our lab-
oratory, it has been reported that EGFR was elevated in cells
found to display a superinvasive phenotype when compared
to the parental cells [5].
Interactions between carcinoma cells and macrophages
promote tumour invasion and metastasis. This promotion of
invasion is mediated by a paracrine loop between the two cell
types involving EGF and CSF-1 (colony-stimulating factor-1)
that enhances chemotactic cell migration of the two cell
types. Macrophages along with other cell types secrete EGF
that stimulates the formation of invadpodia through a series
of intracellular pathways. CSF-1 is a central element in the
paracrine loop, and is produced by carcinoma cells thereby
acting to recruit macrophages to the tumour cells through
the stimulation of the macrophage colony-stimulating factor
receptors and subsequently promoting invasion. Yamaguchi
et al. [42] have also shown that macrophage podosomes can
degrade the ECM after localising to the site of the tumour,
assisting in the invasive process.
The hepatocyte growth factor (HGF) receptor, also called
c-Met, is activated by HGF, a paracrine factor secreted by
stromal and mesenchymal cells. c-Met is overexpressed or
modified in a variety of carcinomas including lung, pancreas
and breast [43]. In patients with invasive breast cancer, Met
or HGF expression is an independent predictor of poor
prognosis [44]. HGF and Met have been implicated in the
modulation of the actin cytoskeleton and in the secretion of
MMPs that degrade and remodel the ECM in certain carci-
nomas including human synovial sarcoma [45, 46]. Davies et
al. [47] demonstrated that by targeting the HGF/scatter factor
(SF) receptor c-met using a hammerhead ribozyme trans-
gene, they could reduce in vitro invasion and migration in
prostate cancer cells. In our laboratory, it has been reported
that a 50 kDa truncated form of c-Met was elevated in MDA-
MB-435S-F/Adr-10p10pSI, a superinvasive population of
cells when compared to the parental cells [5].
CXCR4 also called fusin, is a chemokine receptor in the
GPCR gene family, and is expressed by cells in the immune
system and the CNS. In response to binding its ligand SDF-1
(stromal cell-derived factor-1/CXC chemokine ligand-12),
CXCR4 triggers the migration/recruitment of immune cells
and activates downstream pathways such as ras and PI3
kinase. Breast cancer cells expressing CXCR4 undergo actin
cytoskeleton remodelling upon SDF-1 stimulation, resulting
in the formation of actin-filled protrusions [48].
6 Membrane proteins as diagnostic/
prognostic markers and therapeutic
targets
Membrane and membrane-associated proteins involved in
the invasive potential of tumour cells and subsequent
metastasise to secondary sites are a major source of prog-
nostic indicators in a variety of cancers. For example, CAMs,
such as E-cadherin, integrins and CD44 appear to have some
prognostic significance. Many membrane and membrane-
associated proteins involved in cancer invasion are attractive
targets for pharmaceutical intervention. Integrins have
become attractive targets for drug development, and several
effective integrin antagonists are now under clinical evalua-
tion. Limited agents targeted at tumour or endothelial cell
adhesion has entered clinical trials, but several are under
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development. New therapeutics feature the use of peptido-
mimetics and mAb targeted against many membrane and
membrane-associated proteins.
6.1 Diagnostic/prognostic markers
Loss of E-cadherin expression has been shown to correlate
with invasion and metastasis in many types of carcinoma
[49]. Madhavan et al. [50] reported that the expression of E-
cadherin and P-cadherin showed significant down-regula-
tion in node-positive tumours compared to node-negative
tumours when examined by IHC in 51 cases of breast cancer
that included 29 node-negative and 22 node-positive cases.
Integrins are actively involved in the invasive potential of
tumour cell, with different isoforms associated with particu-
lar cancers and the aggressiveness of the malignancy. Gross-
man et al. examined frozen sections of bladder tumours,
urine specimens, and bladder wash specimens from 59
patients, comparing the level of integrin a6b4 with patient
outcomes. Patients with the invasive form of cancer who
strongly expressed a6b4 had a significantly shorter survival
time than patients who expressed a6b4 weakly or not at all
[51]. Levels of integrins in biofluids such as serum, is a sig-
nificant development allowing for rapid screening and
investigation into the status of the tumour with respect to the
invasive and metastatic potential. Ke et al. have recently
reported that integrin b1 levels in serum were highly expres-
sed in patients with gastric carcinoma before operation or
with unresectable tumours compared to a control group. The
expression levels decreased substantially in the postoperative
patients subjected to radical resection of the tumours, indi-
cating that the high level expressions of integrin b1 might be
the important factor for predicting the prognosis of these
patients [52].
CD44 proteins are released in soluble form (solCD44) by
the action of MMP (MT1-MMP). The soluble 70-kDa frag-
ment is detectable in blood where its levels are correlated
with increased invasive and metastatic potential in some
tumours [53, 54].
Galectin-3, a member of the b-galactoside-binding ani-
mal lectins, has been implicated in tumour invasion and
metastasis. Serum levels of galectin-3 have been reported to
predict progression and the invasive and metastatic potential
of many cancers. Iurisci et al. assessed the circulating levels
of galectin-3 in sera from cancer patients as well as from
healthy controls. Low serum levels of galectin-3 were detect-
ed in healthy individuals (median, 62 ng/mL). Compared
with healthy individuals, galectin-3 serum levels in patients
with breast, gastrointestinal, lung or ovarian cancer, mela-
noma and non-Hodgkin’s lymphoma were significantly ele-
vated. Moreover, galectin-3 concentrations in sera from
patients with metastatic disease were higher than in sera
from patients with localised tumours. Maximum serum
concentrations of galectin-3 (median, 320 ng/mL) were
found in patients with metastatic gastrointestinal carcinoma
[55].
Reports on EGFR and associated receptors have estab-
lished a link between serum levels of these receptors and the
invasive and metastatic potential of certain cancers. The
extracellular binding region of these two receptors for EGFR
and HER2 are proteolytically released from the cell surface
upon receptor activation and can be detected in patients’
serum. In a study performed by Asgeirsson et al., both
sEGFR and sHER2 levels changed significantly between the
times of primary and metastatic diagnosis. Serum EGFR
levels were found to be significantly higher in healthy indi-
viduals than in primary breast cancer patients [56]. Quaranta
et al. discovered that the EGFR was elevated in 47 out of 65
brain cancer patients, with mean serum values of 84 ng/mL,
compared with that of healthy controls which was 43.6 ng/
mL and concluded that measurement in serum of the EGFR
extracellular domain may be potentially useful as a biological
marker of gliomas for the prediction of prognosis and follow-
up after treatment [57].
6.2 Therapeutic targets
The avb3 integrin is an adhesion receptor implicated in
tumour cell invasion and osteoclast-mediated bone resorp-
tion. Zhao et al. data show that tumour avb3 integrin stands
as a therapeutic target for the prevention of skeletal metas-
tases. The nonpeptide antagonist of avb3 (PSK1404) showed
a meaningful antitumour effects in experimental breast and
ovarian cancer bone metastasis [58]. Vitaxin, an antihuman
avb3 antibody is currently in clinical trials as a treatment for
metastatic melanoma and results indicate that this drug may
be instrumental in inhibiting the advancement of life-
threatening cancers [59].
N-cadherin which is associated with increased tumour
invasiveness is a potential novel therapeutic target. The epi-
thelial–mesenchymal transition characterised by the loss of
E-cadherin and the de novo expression of N-cadherin adhe-
sion molecules, highlights N-cadherin as a major target for
pharmaceutical intervention. A peptidic N-cadherin antago-
nist (ADH-1) has been developed and has entered clinical
testing. Shintani et al. [60] recently demonstrated that the N-
cadherin antagonist, ADH-1 has significant antitumour ac-
tivity against N-cadherin-expressing cells using in vitro
assays and in an orthotopic mouse model for pancreatic
cancer, raising the possibility that N-cadherin antagonists
have therapeutic potential for the treatment of pancreatic
cancer in humans.
Abnormalities in EGFR functions are associated with all
key features of cancer development and growth, including
invasion and metastatic potential. Aberrant EGFR signalling
can be initiated by several events, such as altered ligand pro-
duction, receptor mutations or deletions and persistent acti-
vation. High levels of EGFR expression are a common fea-
ture of the malignant phenotype in many solid human
tumours. Numerous EGFR inhibitors are under develop-
ment, for example gefitinib and erlotinib that inhibit the
receptor’s intracellular tyrosine kinase activity as well as
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cetuximab and panitumumab that block extracellular ligand
binding. EGFR inhibitors have been shown to effectively de-
crease the invasive and metastatic potential of many types of
aggressive tumours [61].
A wide variety of human cancers exhibit constitutively
dysregulated c-Met activity, either through overexpression of
the c-Met kinase, activating mutations in c-Met, or increased
autocrine or paracrine secretion of the c-Met ligand, HGF/
SF. Increased expression of the receptor tyrosine kinase c-
Met has been shown to correlate with enhanced motility and
invasion. Despite the promise of c-Met as a cancer target, the
discovery of a selective c-Met inhibitor has proved to be a
difficult challenge. Koon et al. [62] recently reported that
using a specific adenosine triphosphate-competitive small-
molecule inhibitor, SU11274, activated c-Met was decreased
in normal and ovarian carcinoma cell lines resulting in a
significant decreased in cell motility and invasion compared
to untreated cells.
Cancer invasion and metastasis have also been linked to
cellular communication via the CXCR4 activated pathways
and receptor inhibitors could potentially prove very impor-
tant as a treatment strategy. Kim et al. [63] have recently
demonstrated that inhibition of the CXCR4/CXCL12 path-
way decreases metastatic disease in two murine tumour
models using CTCE-9908, a small peptide CXCR4 antago-
nist.
7 Modern strategies for the expression
and functional proteomic analysis of
membrane and membrane-associated
proteins
Gel-based strategies for studying membrane proteins at a
proteomic scale often involve the separation of intact mem-
brane proteins using 2-DE, proving especially suitable for
membrane proteins that contain only one TMD. 2-DE is a
powerful electrophoretic method for the separation of com-
plex protein samples that applies IEF in the first dimension
and SDS-PAGE in the second dimension. The addition of
DIGE technology that labels protein samples with fluores-
cent Cye dyes prior to electrophoresis, enables accurate
analysis of differences in protein abundance between sam-
ples and has added greatly to the overall usability of gel-based
systems for proteins separation.
However this technique does not resolve membrane
proteins that contain more than one TMD very well due to
their high hydrophobicity resulting in low solubility and a
high tendency for aggregation. Recently alternative methods
for performing conventional 2-DE on membrane and mem-
brane-associated proteins have been described and success-
fully demonstrated. Zahedi et al. [64] showed the effective-
ness of 2-D benzyldimethyl-n-hexadecylammonium chloride
(BAC)/SDS-PAGE (2-DB) using the cationic detergent BAC
in the first and the anionic detergent SDS in the second di-
mension as a powerful tool for the separation and analysis of
membrane proteins. The 2-DB enabled the identification of
extremely hydrophobic proteins including cytochrome c oxi-
dase subunit I from Saccharomyces cerevisiae with a total of 12
known TMD’s. Membrane proteins identified using 2-DB
demonstrated significantly higher hydrophobicity, as meas-
ured by increased GRAVY indices [65]. As an alternative to
BAC, Helling et al. [66] used 2-D cetyl trimethyl ammonium
bromide (CTAB)/SDS-PAGE with fluorescence dye satura-
tion labelling (satDIGE) to analyse small quantities of mem-
brane proteins from mouse T-cells. The results demon-
strated how valuable and reproducible this technique is for
the separation/quantification of scarce membrane proteins.
Separation of membrane proteins by 1-D SDS-PAGE and
identification by in-gel trypsin digestion and MS analysis has
proved useful for analysing small complexes of hydrophobic
proteins. However for more complex samples, 1-D SDS-
PAGE alone is insufficient for adequate separation as
demonstrated by Moebius et al. [67] who reported finding ten
or more proteins per band in a typical 1-DE separation. The
1-DE can be combined with many chromatographic tech-
niques such as RP separation of proteins, and has proved to
be very successful in the analysis of complex membrane
proteins. Cao et al. [68] analysed isolated PM proteins using
SDS-PAGE and microcapillary RP LC-MS/MS to identify 428
proteins, including 204 integral membrane or membrane-
associated proteins.
New advances in quantitative proteomic analysis includ-
ing stable isotope labelling with amino acids in cell culture
(SILAC), ICAT and iTRAQ as well as multidimensional pro-
tein identification technology (MudPIT) have increased the
capability of proteomic methods to study the expression
levels of membrane proteins. Together with MS-based pro-
teomics strategies, such technologies have allowed for the
analysis and quantitation of many membrane and mem-
brane-associated proteins previously found to be difficult to
perform. SILAC has proven to be very successful for the
identification of membrane proteins in various cell culture
models. Quantification of membrane and membrane-bound
proteins in normal and malignant breast cancer cells was
performed by Liang et al. [69] using SILAC. Proteins identi-
fied in this study included G proteins, G binding proteins,
farnesyltransferases, ephrins, integrins, porins, a-catenin
and EGFR precursor demonstrating how powerful SILAC is
for the analysis of membrane and membrane-associated
proteins. Given the large amount of cell culture models
available for work on cancer invasion and metastasis, SILAC
will undoubtedly prove to be popular for the identification of
membrane proteins associated with these phenotypes. Using
ICAT, Ramus et al. [70] showed that labelling of highly
hydrophobic proteins with cleavable ICAT is possible and
may even be improved in strong denaturing buffers con-
taining both SDS at a concentration higher than 0.5% w/v
and urea.
Cell culture models are especially useful when studying
the roles of specific membrane and membrane-associated
proteins in invasion and metastasis. Using siRNA knock-
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down and/or cDNA overexpression coupled with a cell
culture-based assay (invasion/motility/adhesion), the par-
ticular function of proteins can be assessed to a greater
extent. Recently new functional proteomics screens using
fluorophore-assisted light inactivation (FALI) for acute
protein knockdown directed by specific binders have been
developed. FALI is a high-throughput method of damaging
proteins in situ by using fluorescein-labelled binders and
490 nm diffuse light [71]. Eustace et al. used both RNA-
mediated interference (RNAi) and FALI screens to identify
the molecular chaperone hsp90 as an important extra-
cellular mediator of invasion. Inhibition of extracellular
hsp90 decreases both MMP2 activity and invasiveness
demonstrating the effectiveness of both functional screens
[72].
Membrane and membrane-associated proteins form
part of complexes that work together to perform specific
processes within a cell. Identification of all the members of
particular complexes is important to the overall under-
standing of how individual proteins participate and interact
with each other. Routine cloning techniques, tagging sys-
tems including His/GST/Flag tags and associated purifica-
tion columns allow for the isolation of specific protein
complexes and their identification through MS [73]. Cell
culture models of cancer invasion and metastasis also
afford the opportunity to image protein localisation and
protein–protein interactions in live cells. New fluorescent
labelling technologies coupled with advanced light micro-
scope techniques make visualising and monitoring pro-
cesses in living cells accessible. Fusion membrane or
membrane-associated proteins containing GFP sequences
may be recombinantly expressed and subsequently mon-
itored in the intact cell with the use of fluorescence reso-
nance energy transfer (FRET) for example [74].
8 Conclusions and perspectives
Membrane and membrane-associated proteins play a vital
role in numerous cellular functions. We have summarised
here the involvement of many membrane proteins in
tumour cell invasion. The majority of membrane proteins
involved in tumour progression are generally of low abun-
dance, difficult to solubilise and can contain numerous
PTMs making analysis more difficult than soluble proteins.
The rapid growth in proteomics technologies, including
separation techniques coupled with MS has also coincided
with advances in sample preparation and protein isolation,
especially for membrane proteins making analysis now more
assessable [75–77].
Many of these proteins are found to be active in many of
the interdependent stages of tumour progression and have a
variety of complex functions as part of the malignancy.
Membrane proteins are attractive as therapeutic targets and
many new treatment regimes target specific molecules
involved in tumour cell invasion successfully. Many mem-
brane proteins are now actively employed as markers of dis-
ease state, providing valuable information that allows for
greater control of therapeutic choice.
The authors have declared no conflict of interest.
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